当前位置： SCI文献检索 > SCHIZOPHRENIA RESEARCH期刊下所有文献 > Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.

Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.

Abstract：

:Second-generation antipsychotics have demonstrated efficacy for patients with schizophrenia but are associated with wide-ranging side effects. Brexpiprazole, a serotonin-dopamine activity modulator, has demonstrated efficacy in adult patients with schizophrenia. This paper provides an overview of the safety and tolerability of brexpiprazole in patients with schizophrenia through examination of pooled safety data from one Phase 2 and two Phase 3 6-week, short-term studies, and two open-label, 52-week, long-term studies. In the short-term studies, there were no reports of treatment-emergent adverse events (TEAEs) with an incidence≥5% and twice that of placebo in patients treated with brexpiprazole 2-4mg. In the long-term studies, TEAEs reported by ≥5% of patients were schizophrenia (10.7%), insomnia (8.0%), weight increase (7.7%), headache (6.0%), and agitation (5.2%). Akathisia rates were low in the short- (5.8%, pooled brexpiprazole group) and long-term studies (4.6%). Sedation rates were low in the short- (2.3%, pooled brexpiprazole group) and long-term studies (0.9%). Mean body weight increase was 1.1kg in both short- and long-term studies. For all studies, changes from baseline to last visit in laboratory parameters, electrocardiogram values, and vital signs were small and not clinically relevant. Changes in lipid profiles or other metabolic parameters were also small. Collectively, these studies suggest that brexpiprazole was well tolerated, with a favorable safety profile that does not exhibit significant rates of important adverse events that can be seen with existing antipsychotics (akathisia, sedation, weight gain, or QTc prolongation), and therefore may provide a useful treatment option for patients with schizophrenia. ClinicalTrials.gov: NCT00905307; NCT01396421; NCT01393613; NCT01649557; NCT01397786.

journal_name

Schizophr Res

journal_title

Schizophrenia research

authors

Kane JM,Skuban A,Hobart M,Ouyang J,Weiller E,Weiss C,Correll CU

doi

10.1016/j.schres.2016.04.013

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

93-98

issue

1-3

eissn

0920-9964

issn

1573-2509

pii

S0920-9964(16)30162-1

journal_volume

174

pub_type

杂志文章,meta分析,评审

在线工具

Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.